Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody and diagnostic kit

An antibody, truncation mutation technology, applied in the field of diagnosis of hereditary breast and ovarian cancer, to achieve the effect of simple operation, high accuracy and low cost

Active Publication Date: 2011-11-16
HUZHOU SHUWEN BIOTECH
View PDF3 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the current detection methods have not been able to meet the high accuracy and low cost requirements we expect.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody and diagnostic kit
  • Antibody and diagnostic kit
  • Antibody and diagnostic kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] In order to prepare antibodies that can selectively immunoreact with the C-terminus of the peptide encoded by the 11th exon of the human BRCA1 gene (the 11th exon antibody), we first synthesized the sequence as TGLEENNQEEQSMDSNL (as shown in SEQ ID NO: 3) Shown) the polypeptide, and then link this polypeptide to keyhole limpet halanin (KLH) to immunize mice. Next, the antisera of the immunized mice were subjected to enzyme-linked immunoassay (ELISA) and Western blot detection (Western Blot) of MCF-7 cells, respectively. The mouse serum was screened by immunohistochemical assay (IHC) of MCF-7 cells and tumor sample cells to obtain the optimal antiserum, and the corresponding mice were used for spleen dissection and hybridoma cell preparation. Supernatants from different hybridoma cell lines were screened by Western blot of cell samples, IHC detection of tissue samples from breast cancer patients with mutations in exon 11, and tissue samples from breast cancer patients wi...

Embodiment 2

[0057] Immunofluorescent labeling experiments were carried out on the SKOV-3 cell line without the mutation of the eleventh exon and the cell line UWB1.289 with the mutation of the eleventh exon using the clone monoclonal antibody BZ-98. Specifically, the cells were cultured In a 24-well plate, after washing 3 times with PBS, fix with 4% paraformaldehyde at room temperature for 20 minutes, after washing, rupture the membrane at 37° for 30 minutes. After washing 3 times with PBS, block with 3% BSA for 30 minutes, and then add BZ-98 as primary antibody at 4° overnight. Next, wash 3 times with PBS, add FITC fluorescent secondary antibody diluted with 1% BSA for 30 minutes at room temperature. After washing with PBS for 3 times, stain with Hoechst 33258 for 10 min, and then wash with PBS for 3 times before microscopic examination. The result was that BZ-98 was able to label SKOV-3 cells but not UWB1.289 cells.

Embodiment 3

[0059] MCF-7 and HCC1937 cells were cultured with RPMI-1640 medium containing 10% fetal bovine serum. UWB1.289 cells were cultured with 50% RPMI-1640+50% MEGM medium containing 3% fetal bovine serum. All cells were cultured at 37°C in a humidified environment containing 95% air and 5% carbon dioxide. The cells were broken up, and the cells were collected by centrifugation at 100 g, then, the cells were washed twice with 10 ml of PBS, and fixed with PBS containing 2% formalin for 48 hours. Then wash once with PBS, resuspend in PBS solution containing 2% agarose, embed in paraffin by standard method, and prepare 4 μm paraffin section sections.

[0060] Sections were first deparaffinized in xylene and then dehydrated through graded ethanol prior to immunocytochemical analysis. Each slice was treated with 1% hydrogen peroxide for 20 minutes, then blocked with serum for 20 minutes, and then in a closed container, one of the following primary antibodies was incubated with the slic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

The invention provides a novel antibody that is directed towards a tumor preventing protein specific area. Based on the antibody, the diagnostic method and kit for determining the variation types of BRCA1 protein in breast or ovarian cancer are also provided.

Description

technical field [0001] The present invention mainly relates to a diagnostic reagent and a method for diagnosing diseases using the kit, in particular to using the antibody and the kit containing the antibody to diagnose hereditary breast cancer and ovarian cancer. technical background [0002] Breast cancer is the malignant tumor with the highest incidence rate in women. In the United States, more than 200,000 women are diagnosed with breast cancer every year. In Europe and China, the number of people diagnosed with breast cancer is also above this level. The number of people who die of breast cancer in the world exceeds five hundred thousand. However, if diagnosed early, the prognosis of breast cancer is quite optimistic. For example, only about 20% of breast cancer patients diagnosed at stage IV survive beyond 5 years, while almost 100% of patients diagnosed at stage I survive beyond 5 years. In contrast, although ovarian cancer is much less common, it is one of the dea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/18C07K16/06C12P21/08C12N5/20A01K67/027G01N33/68G01N33/577
CPCG01N33/57415G01N33/57449C07K16/3015
Inventor 祝建
Owner HUZHOU SHUWEN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com